RxDoctor Payments Data

Mark Robbins, MD

Interventional Cardiology · Nashville, TNNPI 1538256672

Payments from drug & device makers

$13,824in general payments, 2019–2025

Across 22 payments — averaging $628.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$12K
  • Cardiovascular Systems Inc.$891
  • Shockwave Medical, Inc$288
  • Boston Scientific$93
  • Amgen$79
  • Inspire Medical Systems, Inc.$42
  • plus $152 from 6 others

What the payments were for

  • Travel & lodging$89149%
  • Food & beverage$91051%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,824 in reported general payments places this provider in the 60th percentile of 207 interventional cardiology providers in Tennessee.

See all interventional cardiology providers in Tennessee

Medicare billing

Part B allowed, 2024
$265,872
Medicare patients
956
Services billed
1,836

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban191$208,069
XareltoRivaroxaban71$74,025
Repatha SureclickEvolocumab76$63,452
Atorvastatin Calcium295$3,860
Losartan Potassium273$3,716
Clonidine25$2,938
Carvedilol330$2,671
Metoprolol Succinate137$2,304
Rosuvastatin Calcium122$2,249
ClopidogrelClopidogrel Bisulfate222$2,215
Nebivolol Hcl16$2,163
Ranolazine ErRanolazine20$2,030
Ezetimibe24$1,699
Amlodipine Besylate218$1,174
Potassium Chloride91$1,147

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$15$208,069191 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 207 interventional cardiology providers in Tennessee.

Other interventional cardiology in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →